Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PR61
- Development stage
- Preclinical
- Lead developer
- TheraPTEN
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
PR61 is a preclinical mRNA-based therapeutic developed by TheraPTEN designed to restore functional PTEN activity in PTEN-deficient cancer cells. The therapy consists of mRNA encoding a patented, secretable, and cell-permeable albumin-PTEN fusion protein encapsulated within a lipid nanoparticle (LNP). Following intravenous administration, the mRNA is primarily taken up and expressed by the liver, which then secretes the functional PTEN fusion protein into the systemic circulation. This "Trojan Horse" delivery mechanism allows the protein to enter distant tumor cells, where it acts as a tumor suppressor by antagonizing the PI3K/AKT/mTOR signaling pathway. PR61 is being investigated for orphan cancer indications, major PTEN-deficient cancers, and potentially for longevity and healthy aging applications.
- Other names
- albumin-PTEN fusion genealbumin-PTEN fusion proteinPR61 mRNAPR-61 mRNAPR 61 mRNAsecretable and cell-permeable PTEN
02
Targets
PIP3 (Phosphatidylinositol 3,4,5-trisphosphate)FCGRT (Neonatal crystallizable fragment receptor)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)
Beyond the preview
Go deeper on PR61.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PR61.